BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Blood-brain barrier-on-a-chip for brain disease modeling and drug testing

  • Received : 2022.01.31
  • Accepted : 2022.03.22
  • Published : 2022.05.31
Download PDF
⟨ Previous Next ⟩

Abstract

The blood-brain barrier (BBB) is an interface between cerebral blood and the brain parenchyma. As a gate keeper, BBB regulates passage of nutrients and exogeneous compounds. Owing to this highly selective barrier, many drugs targeting brain diseases are not likely to pass through the BBB. Thus, a large amount of time and cost have been paid for the development of BBB targeted therapeutics. However, many drugs validated in in vitro models and animal models have failed in clinical trials primarily due to the lack of an appropriate BBB model. Human BBB has a unique cellular architecture. Different physiologies between human and animal BBB hinder the prediction of drug responses. Therefore, a more physiologically relevant alternative BBB model needs to be developed. In this review, we summarize major features of human BBB and current BBB models and describe organ-on-chip models for BBB modeling and their applications in neurological complications.

Keywords

Acknowledgement

This work was supported by Samsung Research Funding & Incubation Center of Samsung Electronics (Project Number SRFC-TC2003-03).

References

  1. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR and Begley DJ (2010) Structure and function of the blood-brain barrier. Neurobiol Dis 37, 13-25 https://doi.org/10.1016/j.nbd.2009.07.030
  2. Obermeier B, Daneman R and Ransohoff RM (2013) Development, maintenance and disruption of the blood-brain barrier. Nat Med 19, 1584-1596 https://doi.org/10.1038/nm.3407
  3. Abbott NJ, Ronnback L and Hansson E (2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7, 41-53 https://doi.org/10.1038/nrn1824
  4. Huber JD, Egleton RD and Davis TP (2001) Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci 24, 719-725 https://doi.org/10.1016/S0166-2236(00)02004-X
  5. Abbott NJ (2013) Blood-brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis 36, 437-449 https://doi.org/10.1007/s10545-013-9608-0
  6. Schinkel AH (1999) P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 36, 179-194 https://doi.org/10.1016/S0169-409X(98)00085-4
  7. De Bock M, Van Haver V, Vandenbroucke RE, Decrock E, Wang N and Leybaert L (2016) Into rather unexplored terrain-transcellular transport across the blood-brain barrier. Glia 64, 1097-1123 https://doi.org/10.1002/glia.22960
  8. Pardridge WM (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2, 3-14 https://doi.org/10.1602/neurorx.2.1.3
  9. Banks WA (2016) From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov 15, 275-292 https://doi.org/10.1038/nrd.2015.21
  10. Geldenhuys WJ, Allen DD and Bloomquist JR (2012) Novel models for assessing blood-brain barrier drug permeation. Expert Opin Drug Metab Toxicol 8, 647-653 https://doi.org/10.1517/17425255.2012.677433
  11. Hajal C, Le Roi B, Kamm RD and Maoz BM (2021) Biology and models of the blood-brain barrier. Annu Rev Biomed Eng 23, 359-384 https://doi.org/10.1146/annurev-bioeng-082120-042814
  12. Van Norman GA (2019) Limitations of animal studies for predicting toxicity in clinical trials: is it time to rethink our current approach? JACC Basic Transl Sci 4, 845-854 https://doi.org/10.1016/j.jacbts.2019.10.008
  13. Dawson TM, Golde TE and Lagier-Tourenne C (2018) Animal models of neurodegenerative diseases. Nat Neurosci 21, 1370-1379 https://doi.org/10.1038/s41593-018-0236-8
  14. Akhtar A (2015) The flaws and human harms of animal experimentation. Camb Q Healthc Ethics 24, 407-419 https://doi.org/10.1017/S0963180115000079
  15. Bowman PD, Ennis SR, Rarey KE, Betz AL and Goldstein GW (1983) Brain microvessel endothelial cells in tissue culture: a model for study of blood-brain barrier permeability. Ann Neurol 14, 396-402 https://doi.org/10.1002/ana.410140403
  16. Rauh J, Meyer J, Beuckmann C and Galla HJ (1992) Development of an in vitro cell culture system to mimic the blood-brain barrier. Prog Brain Res 91, 117-121 https://doi.org/10.1016/S0079-6123(08)62325-0
  17. Stone NL, England TJ and O'Sullivan SE (2019) A novel transwell blood brain barrier model using primary human cells. Front Cell Neurosci 13, 230 https://doi.org/10.3389/fncel.2019.00230
  18. Srinivasan B, Kolli AR, Esch MB, Abaci HE, Shuler ML and Hickman JJ (2015) TEER measurement techniques for in vitro barrier model systems. J Lab Autom 20, 107-126 https://doi.org/10.1177/2211068214561025
  19. Clevers H (2016) Modeling development and disease with organoids. Cell 165, 1586-1597 https://doi.org/10.1016/j.cell.2016.05.082
  20. Pham MT, Pollock KM, Rose MD et al (2018) Generation of human vascularized brain organoids. Neuroreport 29, 588-593 https://doi.org/10.1097/WNR.0000000000001014
  21. Qian X, Song H and Ming GL (2019) Brain organoids: advances, applications and challenges. Development 146, dev166074 https://doi.org/10.1242/dev.166074
  22. Shi Y, Sun L, Wang M et al (2020) Vascularized human cortical organoids (vOrganoids) model cortical development in vivo. PLoS Biol 18, e3000705 https://doi.org/10.1371/journal.pbio.3000705
  23. Cakir B, Xiang Y, Tanaka Y et al (2019) Engineering of human brain organoids with a functional vascular-like system. Nat Methods 16, 1169-1175 https://doi.org/10.1038/s41592-019-0586-5
  24. Mansour AA, Goncalves JT, Bloyd CW et al (2018) An in vivo model of functional and vascularized human brain organoids. Nat Biotechnol 36, 432-441 https://doi.org/10.1038/nbt.4127
  25. Wang X, Xu B, Xiang M et al (2020) Advances on fluid shear stress regulating blood-brain barrier. Microvasc Res 128, 103930 https://doi.org/10.1016/j.mvr.2019.103930
  26. van der Meer AD, Poot AA, Feijen J and Vermes I (2010) Analyzing shear stress-induced alignment of actin filaments in endothelial cells with a microfluidic assay. Biomicrofluidics 4, 11103 https://doi.org/10.1063/1.3366720
  27. Xu H, Li Z, Yu Y et al (2016) A dynamic in vivo-like organotypic blood-brain barrier model to probe metastatic brain tumors. Sci Rep 6, 36670 https://doi.org/10.1038/srep36670
  28. Wang YI, Abaci HE and Shuler ML (2017) Microfluidic blood-brain barrier model provides in vivo-like barrier properties for drug permeability screening. Biotechnol Bioeng 114, 184-194 https://doi.org/10.1002/bit.26045
  29. Bhatia SN and Ingber DE (2014) Microfluidic organs-on-chips. Nat Biotechnol 32, 760-772 https://doi.org/10.1038/nbt.2989
  30. Duffy DC, McDonald JC, Schueller OJ and Whitesides GM (1998) Rapid prototyping of microfluidic systems in poly(dimethylsiloxane). Anal Chem 70, 4974-4984 https://doi.org/10.1021/ac980656z
  31. Xia Y and Whitesides GM (1998) Soft lithography. Angew Chem Int Ed Engl 37, 550-575 https://doi.org/10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.0.CO;2-G
  32. Viravaidya K, Sin A and Shuler ML (2004) Development of a microscale cell culture analog to probe naphthalene toxicity. Biotechnol Prog 20, 316-323 https://doi.org/10.1021/bp0341996
  33. Sin A, Chin KC, Jamil MF, Kostov Y, Rao G and Shuler ML (2004) The design and fabrication of three-chamber micro-scale cell culture analog devices with integrated dissolved oxygen sensors. Biotechnol Prog 20, 338-345 https://doi.org/10.1021/bp034077d
  34. Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Hsin HY and Ingber DE (2010) Reconstituting organ-level lung functions on a chip. Science 328, 1662-1668 https://doi.org/10.1126/science.1188302
  35. Zhang B, Korolj A, Lai BFL and Radisic M (2018) Advances in organ-on-a-chip engineering. Nat Rev Mater 3, 257-278 https://doi.org/10.1038/s41578-018-0034-7
  36. Zhang B and Radisic M (2017) Organ-on-a-chip devices advance to market. Lab Chip 17, 2395-2420 https://doi.org/10.1039/C6LC01554A
  37. Ma C, Peng Y, Li H and Chen W (2021) Organ-on-a-chip: a new paradigm for drug development. Trends Pharmacol Sci 42, 119-133 https://doi.org/10.1016/j.tips.2020.11.009
  38. Reardon S (2015) 'Organs-on-chips' go mainstream. Nature 523, 266 https://doi.org/10.1038/523266a
  39. Park TE, Mustafaoglu N, Herland A et al (2019) Hypoxia-enhanced blood-brain barrier chip recapitulates human barrier function and shuttling of drugs and antibodies. Nat Commun 10, 2621 https://doi.org/10.1038/s41467-019-10588-0
  40. Seo S, Nah SY, Lee K, Choi N and Kim HN (2021) Triculture model of in vitro BBB and its application to study BBB-associated chemosensitivity and drug delivery in glioblastoma. Adv Funct Mater 32, 2106860
  41. Bang S, Lee SR, Ko J et al (2017) A low permeability microfluidic blood-brain barrier platform with direct contact between perfusable vascular network and astrocytes. Sci Rep 7, 8083 https://doi.org/10.1038/s41598-017-07416-0
  42. Urich E, Patsch C, Aigner S, Graf M, Iacone R and Freskgard PO (2013) Multicellular self-assembled spheroidal model of the blood brain barrier. Sci Rep 3, 1500 https://doi.org/10.1038/srep01500
  43. Cho CF, Wolfe JM, Fadzen CM et al (2017) Blood-brain-barrier spheroids as an in vitro screening platform for brain-penetrating agents. Nat Commun 8, 15623 https://doi.org/10.1038/ncomms15623
  44. Eilenberger C, Rothbauer M, Selinger F et al (2021) A microfluidic multisize spheroid array for multiparametric screening of anticancer drugs and blood-brain barrier transport properties. Adv Sci (Weinh) 8, e2004856
  45. Rosenberg GA (2012) Neurological diseases in relation to the blood-brain barrier. J Cereb Blood Flow Metab 32, 1139-1151 https://doi.org/10.1038/jcbfm.2011.197
  46. Schoknecht K and Shalev H (2012) Blood-brain barrier dysfunction in brain diseases: clinical experience. Epilepsia 53 Suppl 6, 7-13 https://doi.org/10.1111/j.1528-1167.2012.03697.x
  47. Daneman R (2012) The blood-brain barrier in health and disease. Ann Neurol 72, 648-672 https://doi.org/10.1002/ana.23648
  48. Sweeney MD, Sagare AP and Zlokovic BV (2018) Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol 14, 133-150 https://doi.org/10.1038/nrneurol.2017.188
  49. Yoon JK, Kim J, Shah Z, Awasthi A, Mahajan A and Kim Y (2021) Advanced human BBB-on-a-chip: a new platform for Alzheimer's disease studies. Adv Healthc Mater 10, e2002285
  50. Drummond E and Wisniewski T (2017) Alzheimer's disease: experimental models and reality. Acta Neuropathol 133, 155-175 https://doi.org/10.1007/s00401-016-1662-x
  51. Golaszewska A, Bik W, Motyl T and Orzechowski A (2019) Bridging the gap between Alzheimer's disease and Alzheimer's-like diseases in animals. Int J Mol Sci 20, 1664 https://doi.org/10.3390/ijms20071664
  52. Cummings J, Feldman HH and Scheltens P (2019) The "rights" of precision drug development for Alzheimer's disease. Alzheimers Res Ther 11, 76 https://doi.org/10.1186/s13195-019-0529-5
  53. Shin Y, Choi SH, Kim E et al (2019) Blood-brain barrier dysfunction in a 3D in vitro model of Alzheimer's disease. Adv Sci (Weinh) 6, 1900962 https://doi.org/10.1002/advs.201900962
  54. Yang C, Hawkins KE, Dore S and Candelario-Jalil E (2019) Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke. Am J Physiol Cell Physiol 316, C135-C153 https://doi.org/10.1152/ajpcell.00136.2018
  55. Wang Y and Cai Y (2016) Obtaining human ischemic stroke gene expression biomarkers from animal models: a cross-species validation study. Sci Rep 6, 29693 https://doi.org/10.1038/srep29693
  56. Xiong Y, Mahmood A and Chopp M (2013) Animal models of traumatic brain injury. Nat Rev Neurosci 14, 128-142 https://doi.org/10.1038/nrn3407
  57. Lyu Z, Park J, Kim KM et al (2021) A neurovascular-unit-on-a-chip for the evaluation of the restorative potential of stem cell therapies for ischaemic stroke. Nat Biomed Eng 5, 847-863 https://doi.org/10.1038/s41551-021-00744-7
  58. Chaudhuri JD (2000) Blood brain barrier and infection. Med Sci Monit 6, 1213-1222
  59. Kim J, Lee KT, Lee JS et al (2021) Fungal brain infection modelled in a human-neurovascular-unit-on-a-chip with a functional blood-brain barrier. Nat Biomed Eng 5, 830-846 https://doi.org/10.1038/s41551-021-00743-8
  60. Buzhdygan TP, DeOre BJ, Baldwin-Leclair A et al (2020) The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood-brain barrier. Neurobiol Dis 146, 105131 https://doi.org/10.1016/j.nbd.2020.105131
  61. Kim Y, Stolarska MA and Othmer HG (2011) The role of the microenvironment in tumor growth and invasion. Prog Biophys Mol Biol 106, 353-379 https://doi.org/10.1016/j.pbiomolbio.2011.06.006
  62. Kim HN, Habbit NL, Su CY et al (2019) Microphysiological systems as enabling tools for modeling complexity in the tumor microenvironment and accelerating cancer drug development. Adv Funct Mater 29, 1807553 https://doi.org/10.1002/adfm.201807553
  63. Pardridge WM (2007) Blood-brain barrier delivery. Drug Discov Today 12, 54-61 https://doi.org/10.1016/j.drudis.2006.10.013
  64. Ahn SI, Sei YJ, Park HJ et al (2020) Microengineered human blood-brain barrier platform for understanding nanoparticle transport mechanisms. Nat Commun 11, 175 https://doi.org/10.1038/s41467-019-13896-7